HilleVax to Present at Upcoming Investor Conferences
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York, New York on Monday, November 6, 2023 at 3:10 p.m. EST and at the Stifel Healthcare Conference in New York, New York, on Tuesday, November 14, 2023 at 11:30 a.m. EST. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
Related news for (HLVX)
- HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
- HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
- HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
- HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
- HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference